Author

Fernando Salangsang

University of California, San Francisco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

Arun P. WiitaiD· 4 shared Paul J. Phojanakong· 4 shared Veronica SteriiD· 4 shared Amrik S. KangiD· 3 shared Bonell Patiño-EscobariD· 3 shared Adila IzgutdinaiD· 2 shared Emilio Ramos· 2 shared Haley Johnson· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Arun P. WiitaORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Integrative Genomic, Single-Cell, and Functional Profiling of the CD48-CD244 Axis and NK-Cell Dysfunction in Multiple Myeloma

Bonell Patiño-Escobar, Torsten Steinbrunn, Lucy Maritza Pérez Lugo, Sham Rampersaud, Daniel Dirck Waller, Huimin Geng, Fernando Salangsang, Paul J. Phojanakong, Juan Antonio Camara Serrano, Yan Zeng, Veronica Steri, Oscar A. Aguilar, Constantine S. Mitsiades, Arun P. Wiita

The paper investigates the CD48-CD244 axis in multiple myeloma, showing CD48 enhances NK-cell activation but contributes to NK exhaustion and poor prognosis.

bioRxiv · May 12, 2026 · PreprintCancer Biology

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies

Adila Izgutdina, Tasfia Rashid, William C. Temple, Sarah Aminov, Bonell Patiño-Escobar, Sujata B. Walunj, Huimin Geng, Hiroyuki Takamatsu, Daniel Gil-Alós, Amrik S. Kang, Emilio Ramos, Szu‐Ying Chen, Haley Johnson, Matthew A. Nix, Akul Naik, , Arun P. Wiita

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

Journal for ImmunoTherapy of Cancer · Dec 1, 2025Peer-reviewedImmunology

Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia

Amrik S. Kang, H. A. Johnson, Nicole Lei, Jeremiah Wong, Nabeel Razi, Adila Izgutdina, Corynn Kasap, Nikhil Chilakapati, Jose M. Rivera, Paul J. Phojanakong, Juan A. Cámara, Fernando Salangsang, Veronica Steri, Aaron C. Logan, Justin Eyquem, , Arun P. Wiita

This paper develops dual-antigen targeting CAR-T cells against CD70 and active integrin β2 to overcome AML antigen heterogeneity and reduce off-tumor toxicity.

bioRxiv · Sep 21, 2025 · PreprintImmunology

Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma

Nikhil Chilakapati, Bonell Patiño-Escobar, Emily Y. Chen, Radhika Dalal, Jonathan de Montagnac, Haley Johnson, Amrik S. Kang, Naomi Akagi, Emilio Ramos, Paul J. Phojanakong, Fernando Salangsang, Yan Zeng, Ajai Chari, Alfred Chung, Anupama Deepa Kumar, , Arun P. Wiita

This paper engineers CCL27 mutants to enhance CAR T-cell efficacy against multiple myeloma by targeting CCR10, achieving results comparable to BCMA CAR-Ts.

bioRxiv · Aug 19, 2025 · PreprintCancer Biology